The combination of smoking and socioeconomic status (SES) is associated with risk of asthma among different socio-occupational groups, this new study found.
In addition to independent risk factors, the interaction between smoking and socioeconomic status (SES) was found to be associated with risk of respiratory illnesses, such as asthma, according to a new study.
“This study found putative interactions between smoking and different measures of SES in relation to the probability of having respiratory diseases,” wrote the study researchers. “Education and occupational classification, as different measures of SES, presented different patterns of smoking association with asthma, when the latter is divided by allergic status.”
The results of this population-based analysis were published in Respiratory Medicine.
The researchers used data from the West Sweden Asthma Study (WSAS), which included 23,753 participants, and the Obstructive Lung Disease in Northern (OLIN) studies, which included 6519 participants. All participants included in the analysis were randomly selected adults aged 20 to 75 years living in Sweden in 2016.
All participants received a questionnaire that consisted of 3 parts, with questions pertaining to the following:
In total, the finaly analysis sample included 30,123 participants:
As a result, the study found education and occupation presented different smoking associations between allergic and nonallergic asthma status.
Respiratory problems associated with smoking and allergic asthma was more profound among manual workers in service and intermediate nonmanual employees than in high professional and executive workers. However, the prevalence of allergic asthma was higher among highly educated groups compared with lower-educated groups.
In contrast, adverse smoking effects and nonallergic asthma were more prevalent among high occupational workers compared with manual and home workers. However, nonallergic asthma status was more prevalent among low0-educated groups compared with highly educated groups.
The results of this study suggest that certain high-risk social and occupational groups may benefit from individualized smoking cessation interventions more than others. In addition, the researchers believe that more research is needed to fully understand the mechanism behind the interaction of smoking and occupation exposures to reduce the risk of asthma among different SES and occupational settings.
“In conclusion, this study showed that beyond the independent role of smoking and SES in respiratory diseases, in high-income countries such as Sweden, SES as measured using different socioeconomic classification systems and smoking interact in defining the risk of respiratory diseases in adults,” wrote the researchers. “Better understanding of this interaction can be of help when identifying social and occupational risk groups at higher need of preventive intervention.”
Reference
Bashir MB, Basna R, Hedman L, et al. Interaction of smoking and social status on the risk of respiratory outcomes in a Swedish adult population: a nordic epilung study. Respiratory Medicine. Published online March 9, 2023. doi:10.1016/j.rmed.2023.107192
Federated Learning Models Show Potential in Melanoma-Nevus Classification, but Improvements Needed
March 16th 2024A multicentric, single-arm diagnostic study created a decentralized federated learning model for the classification of invasive melanomas and nevi, showcasing comparable results to centralized data models.
Read More
Alcohol Use Disorder Equally Linked to Suicide Across Genders, Study Finds
March 15th 2024Illuminating the critical intersection of substance use and mental health, these findings underscore the urgent need for comprehensive strategies to address alcohol use disorder within suicide prevention efforts.
Read More
6 Blood Biomarkers Identified to Predict CVD Risk in Patients With Rheumatoid Arthritis
March 15th 2024Baseline levels of serum amyloid A, C‐reactive protein, soluble tumor necrosis factor receptor 1, adiponectin, YKL‐40, and osteoprotegerin could be used to predict a rise in arterial inflammation.
Read More
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis
March 14th 2024The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
Read More